Cerebrovascular Disease
1
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
ETSMO - Rolla
2 programsCollection of clinical, radiological, and biological data from patients' medical recordsN/A1 trial
National Database of the Virtual Institute of Cerebrovascular DiseasesN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Innovation PharmaceuticalsAsprin, Cilostazol
UNION therapeuticsPS-3D-DSA
ETSNational Database of the Virtual Institute of Cerebrovascular Diseases
ETSCollection of clinical, radiological, and biological data from patients' medical records
Clinical Trials (4)
Total enrollment: 598,734 patients across 4 trials
Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis
Start: May 2006Est. completion: Mar 2012200 patients
Phase 3Completed
(Withdrawal) AI-Based Low-Dose 3D-DSA Reconstruction
Start: Apr 2025Est. completion: May 2025134 patients
N/ANot Yet Recruiting
National Database of the Virtual Institute of Cerebrovascular Diseases
Start: Sep 2024Est. completion: Apr 2054312,800 patients
N/ARecruiting
NCT05925699ETSCollection of clinical, radiological, and biological data from patients' medical records
National Database of the Virtual Institute of Cerebrovascular Diseases
Start: Sep 2023Est. completion: Sep 2052285,600 patients
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 598,734 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.